VERA vs HRMY
Side-by-side comparison of price performance, valuation, growth, profitability, analyst targets and technical trend.
VERA · Vera Therapeutics$25.45 ▼ 4.86%
HRMY · Harmony Biosciences$32.59 ▼ 1.18%
One year, rebased to 100
Each line starts at 100 so growth is directly comparable
- VERA -13.0%
- HRMY -7.6%
Head to head
| Metric | VERA | HRMY |
|---|---|---|
| Price | $25.45 | $32.59 |
| Change today | ▼ 4.86% | ▼ 1.18% |
| Market cap | $1.84B | $1.91B |
| Return, 3 months | -24.5% | -15.4% |
| Return, year to date | -49.7% | -12.9% |
| Return, 1 year | -10.6% | -5.0% |
| P/E (TTM) | – | 10.8 |
| P/B | 5.5 | 1.8 |
| P/E percentile vs own 5y | 78th | 17th |
| Dividend yield | – | – |
| Revenue growth (YoY, latest qtr) | – | +12.3% |
| Net profit growth (YoY) | -16.7% | -5.2% |
| Gross margin | 67.9% | 74.0% |
| Operating margin | -4,160.1% | 22.2% |
| Net margin | -4,041.2% | 18.1% |
| Return on equity | -113.5% | 18.7% |
| Analyst target vs. price | +175.8% | +45.8% |
| Analyst buy share | 83% | 63% |
| RSI (14) | 36 | 32 |
| 30-day volatility | 62.4% | 42.9% |
| Max drawdown, 1 year | -54.3% | -34.5% |
| Trend read | Strong downtrend | Strong downtrend |
| Analyst consensus | Buy | Buy |
Green cells mark the best value in each row where "better" is clear-cut (lower P/E, higher margin). That is a reading of the numbers, not a recommendation. Financials are in each company's reporting currency.
What the numbers say
- HRMY is the largest of the group by market value.
- HRMY has returned the most over the past year.
- HRMY keeps the most profit per dollar of sales.
- HRMY has been the calmest stock over the last 30 days.